From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Biotin-4-aminophenol is a biotin-phenol analog. Biotin-4-aminophenol generates free radicals and conjugates to tyrosine residues in proteins more efficiently and selectively than the previously reported BP1[1].
Pim-1/2 kinase inhibitor 1 is an orally active pim-1/2 kinase inhibitor. Pim-1/2 kinase inhibitor 1 blocks the ability of Pim kinases to phosphorylate peptides, and inhibits the pim protein kinase directed phosphorylation of 4E-BP1 and p27 Kip1. Pim-1/2 kinase inhibitor 1 can be used in study of cancer, especially prostate cancer [1].
WRX606 is an inhibitor for mTOR complex 1(mTORC1). WRX606 inhibits the phosphorylation of mTORC1 substrate S6 kinase 1 S6K1 (IC50=10 nM), and the phosphorylation of the eukaryotic translation initiation factor 4E binding protein (p-4E-BP1) (IC50=0.27 μM) in MCF-7. WRX606 exhibits cytotoxicity to HepG2 with IC50 of 17 nM. WRX606 exhibits antitumor efficacy in mouse models [1].
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active [1] .
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) [1].
BP-1-108 is a selective inhibitor of STAT5 (Ki=8.3 μM) with anticancer activity. BP-1-108 induces apoptosis of leukemia cells by inhibiting the phosphorylation of STAT5. BP-1-108 can be used in the study of acute myeloid leukemia and prostate cancer [1].
mTOR inhibitor-2 is a highlt potent, selective and oral mTOR inhibitor with an IC50 of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates [1].
SR-4133 is a potent and highly CK1ε selective inhibitor with an IC50 of 58 nM. SR-4133 binds to the ATP-binding site of CK1ε. SR-4133 displays nanomolar growth inhibition of bladder cancer cells, and inhibits the phosphorylation of 4E-BP1[1].
DM-PIT-1 is a PIP3/PH (phosphatidylinositol-3,4,5-triphosphate/Pleckstrin) interaction inhibitor. DM-PIT-1 decreases he expression of P-Akt, P-GSK-3-β, P-p70S6K, P-S6, P-4E-BP1. DM-PIT-1 induces apoptosis and shows anticancer activity. DM-PIT-1 has the potential for the research of ovarian cancer [1] .
Garcinone C (Standard) is the analytical standard of Garcinone C. This product is intended for research and analytical applications. Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active [1] .
IGF2BP1-IN-1 (Compound A11) is a IGF2BP1 inhibitor and inhibits downstream signaling. IGF2BP1-IN-1 binds to IGF2BP1 protein with a KD value of 2.88 nM. IGF2BP1-IN-1 inhibits cancer cells proliferation (IC50: 9 nM for A549 cell, 34 nM for HCT116). IGF2BP1-IN-1 induces cancer cell apoptosis. GF2BP1-IN-1 inhibits tumor growth in A549 xenograft mouse model [1].
G3BP1/2-Targeting ligand-1 is the ligand for G3BP1/2 that can be used as target protein ligand for synthesis of G3BP1/2 PROTAC degrader PT-129 (HY-170872) [1].
TNKS1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TP53BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TP53BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
IGF2BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for IGF2BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Igf2bp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Igf2bp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Igf2bp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Igf2bp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH3BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for SH3BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
G3bp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for G3bp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Tax1bp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tax1bp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
N4BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for N4BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
G3BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for G3BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
G3bp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for G3bp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
TAX1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TAX1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
IRF2BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for IRF2BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
MIS18BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for MIS18BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ITGB1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for ITGB1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
UNC3474 is a small molecule ligand, binding with 53BP1. UNC3474 binds the aromatic methyl-lysine binding cage of 53BP1TT, with a dissociation constant (Kd) of 1.0 ± 0.3 μM. UNC3474 inhibits the recruitment of 53BP1 to DSBs by stabilizing a pre-existing autoinhibited state of 53BP1 in cells [1].
FAZ-3780 (compound G3Ib) is an inhibitor of binding to the NTF2L domain of G3BP1/2 that binds to G3BP1 with a Kd of 0.15 μM. FAZ-3780 targets the protein-protein interaction domain of G3BP1/2 and specifically inhibits co-condensation of G3BP1, caprin 1, and RNA in vitro [1].
FAZ-3532 (compound G3Ia) is an inhibitor of binding to the NTF2L domain of G3BP1/2 that binds to G3BP1 with a Kd of 0.54 μM. FAZ-3532 targets the protein-protein interaction domain of G3BP1/2 and specifically inhibits co-condensation of G3BP1, caprin 1, and RNA in vitro [1].
AVJ16 is a cancer cell migration inhibitor that targets the insulin-like growth factor 2 mRNA binding protein IGF2BP1 to inhibit the migration of H1299 cells with high endogenous IGF2BP1 expression. AVJ16 interferes with IGF2BP1 binding target mRNA to regulate gene expression and translation [1].
UNC9512 is a potent methyl-lysine reader p53 binding protein 1(53BP1) antagonist. UNC9512 can be used to study the role of 53BP1 in DNA repair, gene editing and tumorigenesis [1].
UNC-2170 is a functionally active, fragment-like ligand for 53BP1 (IC50=29 µM; Kd=22 µM). UNC-2170 shows at least 17-fold selectivity for 53BP1 as compared to nine other methyl-lysine (Kme) reader proteins. 53BP1 is a Kme binding protein that plays a central role in DNA Damage Repair (DDR) pathways and is recruited to sites of double-strand breaks (DSB) [1].
UNC-2170 maleate is the maleate salt form of UNC-2170 (HY-115531). UNC-2170 maleate is a selective inhibitor for the methyl-lysine binding protein 53BP1, with IC50 of 29 µM and Kd of 22 µM. UNC-2170 maleate shows at least 17-fold selectivity for 53BP1 as compared to nine other methyl-lysine (Kme) reader proteins. 53BP1 is a Kme binding protein that plays a central role in DNA Damage Repair (DDR) pathways and is recruited to sites of double-strand breaks (DSB) [1].
PT-129 is an RPOTAC degrader targeting the NTF2 domain (protein-RNA interaction site) of G3BP1/2, which mediates the disassembly of intracellular stress granules. PT-129 can inhibit the formation of stress granules in stressed cells and disassemble existing stress granules, and can disrupt the transmission of ATF4, thereby inhibiting the proliferation of cancer cells. Stress granules (SGs) are membrane-less cytoplasmic compartments formed under stress stimuli. SGs promote the transmission of ATF4 from fibroblasts to tumor cells through a migratory effect, mediating fibroblast-related tumor growth. And G3BP1/2 is a central protein of the SGs network, and the inhibition of G3BP1/2 may reduce the stress resistance of cancer cells in the tumor microenvironment. PT-129 is composed of a target protein ligand (red part) G3BP1/2-Targeting ligand-1 (HY-170873), an E3 ligase ligand (blue part) Thalidomide 4-fluoride (HY-41547), and a PROTAC linker (black part) Amino-PEG3-C2-acid (HY-W040165); among them, the E3 ligase ligand + linker form a complex Thalidomide-NH-PEG3-propionic acid (HY-136166) [1].
Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .
Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
Ranolazine-d8 (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].
Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Ranolazine-d8 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Ranolazine (Standard) is the analytical standard of Ranolazine. This product is intended for research and analytical applications. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
HL001 is an orally active small molecule inhibitor of Cyclophilin A (CypA) and a receptor antagonist of Lysophosphatidic acid 1(LPA1). HL001 induces cell cycle arrest and apoptosis of tumor cells by p53. HL001 stabilizes p53 by down-regulating G3BP1, inducing reactive oxygen species and DNA damage. HL001 disrupts the interaction between MDM2 and p53-72R in a CypA dependent manner. HL001 has antitumor activity. HL001 can also be used to study pulmonary fibrosis [1] .
Tat-peptide 190-208 TFA is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 TFA increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 TFA likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 TFA can be used for ischemic protection during endovascular repair for intracranial aneurysms [1].
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 190-208 (HY-P5118), as Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron [1].
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 168-189 TFA (HY-P5118A), as Tat-peptide 168-189 TFA increases axon growth and increases the number of neurites per neuron [1].
Tat-peptide 190-208 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 can be used for ischemic protection during endovascular repair for intracranial aneurysms [1].
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active [1] .
Garcinone C (Standard) is the analytical standard of Garcinone C. This product is intended for research and analytical applications. Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active [1] .
The ACO1 protein is a bifunctional iron sensor that dynamically adapts to cellular iron levels. Under conditions of iron deficiency, it is converted to mRNA binding and regulates iron-related gene expression. Aconitase 1/ACO1 Protein, Human (sf9, His) is the recombinant human-derived Aconitase 1/ACO1 protein, expressed by Sf9 insect cells , with N-His labeled tag.
Siglec-6 Protein, a putative adhesion molecule, facilitates sialic acid-dependent binding to cells, specifically binding to alpha-2,6-linked sialic acid. Its sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. Siglec-6 interacts with LEP. Siglec-6 Protein, Human (HEK293, Fc) is the recombinant human-derived Siglec-6 protein, expressed by HEK293 , with C-hFc labeled tag.
CD42b/GP1BA protein is an important platelet membrane protein that interacts with the A1 domain of von Willebrand factor and contributes to the formation of subendothelial platelet plugs. Its GP1BA subunit forms a disulfide-linked complex with two GP1BB subunits, collectively called GP-Ib. CD42b/GP1BA Protein, Human (HEK293, His) is the recombinant human-derived CD42b/GP1BA protein, expressed by HEK293 , with C-His labeled tag.
rHuEukaryotic translation initiation factor 4E-binding protein 1/EIF4EBP1, His; Eukaryotic Translation Initiation Factor 4E-Binding Protein 1; 4E-BP1; eIF4E-Binding Protein 1; Phosphorylated Heat- and Acid-Stable Protein Regulated by Insulin 1; PHAS-I; EIF4EBP1
EIF4EBP1 is a translation initiation repressor protein that complexly regulates EIF4E activity. In the hypophosphorylated state, EIF4EBP1 competes with EIF4G1/EIF4G3 to inhibit translation by binding to EIF4E. EIF4EBP1 Protein, Human (His) is the recombinant human-derived EIF4EBP1 protein, expressed by E. coli , with N-6*His labeled tag.
The APPBP1-UBA3/NEDD8 E1 protein is the regulatory subunit in the UBA3-NAE1 E1 enzyme complex and activates NEDD8 by adenylating its C-terminal glycine with ATP. This forms the NEDD8-UBA3 thioester, which is transferred to the catalytic cysteine of UBE2M. APPBP1-UBA3/NEDD8 E1 Protein, Human is a recombinant protein dimer complex containing human-derived APPBP1-UBA3/NEDD8 E1 protein, expressed by E. coli , with tag free. APPBP1-UBA3/NEDD8 E1 Protein, Human, has molecular weight of 60 kDa (APP-BP1) 50 kDa (UBA3).
Syntaxin-BP1 protein critically regulates synaptic vesicle docking and fusion, binds GTP-binding proteins and ensures efficient neurotransmission. It interacts with syntaxin in a 1:1 ratio and shows specificity for syntaxin 1, 2, and 3 (excluding syntaxin 4). Syntaxin-BP1 Protein, Human (sf9, His-GST) is the recombinant human-derived Syntaxin-BP1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.
Siglec-6 Protein, a putative adhesion molecule, facilitates sialic acid-dependent binding to cells, specifically binding to alpha-2,6-linked sialic acid. Its sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. Siglec-6 interacts with LEP. Siglec-6 Protein, Human (HEK293, His-Avi) is the recombinant human-derived Siglec-6 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of Siglec-6 Protein, Human (HEK293, His-Avi) is 305 a.a., with molecular weight of 55-70 kDa.
Ranolazine-d8 (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].
Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Ranolazine-d8 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I
WB, IHC-P, IP
Human, Mouse, Rat, Hamster
4E BP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 13 kDa, targeting to 4E BP1. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat, Hamster.
EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I
WB, IHC-P, IP
Human, Mouse, Rat
Phospho-4E BP1 (Thr46) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 13 kDa, targeting to Phospho-4E BP1 (Thr46). It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.
ATF2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 52 kDa, targeting to ATF2. It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.
53BP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 214 kDa, targeting to TP53BP1. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.
AP-A Antibody (YA2164) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2164), targeting AP-A, with a predicted molecular weight of 109 kDa (observed band size: 160 kDa). AP-A Antibody (YA2164) can be used for WB, IHC-P experiment in human background.
DLX4; BP1; DLX7; DLX8; DLX9; Homeobox protein DLX-4; Beta protein 1; Homeobox protein DLX-7; Homeobox protein DLX-8
WB, ICC/IF, IP
Human, Rat
DLX4 Antibody (YA2697) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2697), targeting DLX4, with a predicted molecular weight of 26 kDa (observed band size: 35 kDa). DLX4 Antibody (YA2697) can be used for WB, ICC/IF, IP experiment in human, rat background.
CELF1; BRUNOL2; CUGBP; CUGBP1; NAB50; CUGBP Elav-like family member 1; CELF-1; 50 kDa nuclear polyadenylated RNA-binding protein; Bruno-like protein 2; CUG triplet repeat RNA-binding protein 1; CUG-BP1; CUG-BP- and ETR-3-like factor 1; Dead
WB, IHC-P, ICC/IF, IP, FC
Human, Mouse, Rat
CUG BP1 Antibody (YA2806) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2806), targeting CUG BP1, with a predicted molecular weight of 52 kDa (observed band size: 52 kDa). CUG BP1 Antibody (YA2806) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human, mouse, rat background.
TAX1BP1 Antibody (YA2248) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2248), targeting TAX1BP1, with a predicted molecular weight of 91 kDa (observed band size: 91 kDa). TAX1BP1 Antibody (YA2248) can be used for WB, IHC-P experiment in human background.
N4BP1 Antibody (YA3286) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3286), targeting N4BP1, with a predicted molecular weight of 99 kDa (observed band size: 99 kDa). N4BP1 Antibody (YA3286) can be used for WB, IP experiment in human background.
CPEB1 Antibody (YA2357) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2357), targeting CPEB1, with a predicted molecular weight of 63 kDa (observed band size: 70 kDa). CPEB1 Antibody (YA2357) can be used for WB, IP experiment in human background.
G3BP1; G3BP; Ras GTPase-activating protein-binding protein 1; G3BP-1; ATP-dependent DNA helicase VIII; hDH VIII; GAP SH3 domain-binding protein 1
WB, IHC-P, ICC/IF, IP, FC
Human, Mouse, Rat
G3BP Antibody (YA2432) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2432), targeting G3BP, with a predicted molecular weight of 52 kDa (observed band size: 68 kDa). G3BP Antibody (YA2432) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human, mouse, rat background.
ACO1; IREB1; Cytoplasmic aconitate hydratase; Aconitase; Citrate hydro-lyase; Ferritin repressor protein; Iron regulatory protein 1; IRP1; Iron-responsive element-binding protein 1; IRE-BP 1
WB, ICC/IF
Human, Mouse, Rat
Aconitase 1 Antibody (YA2850) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2850), targeting Aconitase 1, with a predicted molecular weight of 98 kDa (observed band size: 98 kDa). Aconitase 1 Antibody (YA2850) can be used for WB, ICC/IF experiment in human, mouse, rat background.
IGF2BP1 Antibody (YA3071) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3071), targeting IGF2BP1, with a predicted molecular weight of 63 kDa (observed band size: 63 kDa). IGF2BP1 Antibody (YA3071) can be used for WB, IHC-P, IP experiment in human, mouse background.
Beta Actin Antibody is a non-conjugated and Mouse origined monoclonal antibody about 42 kDa, targeting to Beta Actin. It can be used for WB,ICC,IHC-P assays with tag free, in the background of Human, Mouse, Rat.
TNKS1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TP53BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TP53BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
IGF2BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for IGF2BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Igf2bp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Igf2bp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Igf2bp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Igf2bp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH3BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for SH3BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
G3bp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for G3bp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Tax1bp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tax1bp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
N4BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for N4BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
G3BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for G3BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
G3bp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for G3bp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
TAX1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TAX1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
IRF2BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for IRF2BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
MIS18BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for MIS18BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ITGB1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for ITGB1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
